Immunome, Inc.

IMNM Healthcare Biotechnology

Immunome, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.9 million, down 23.2% from fiscal 2024. In the quarter to June 2026, revenue grew 69.8%, EPS fell 30.0% and free cash flow fell 27.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

16.47 0.93 −5.34%
Market cap
$2.1B
P/E
0.0×
Fwd P/E
−8.7×
Dividend yield
—
F-score
4/9
Altman Z
21.57
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Quick Ratio
14.56 21.26 14.53 8.67
Current Ratio
15.08 21.68 14.69 8.90
Net Debt/EBITDA
6.72 9.95 9.07 4.53
Debt/Assets
0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00
Asset Turnover
0.00 0.00 0.00 0.00
Operating CF/Net income
0.84 1.09 0.69 0.71
Capex/Depreciation
(3.04) (3.99) (5.15) 13.45
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Free Cash Flow Yield
— — — —
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(0.54) (0.52) (0.55) (0.46)
Capex per Share
(0.02) (0.03) (0.05) (0.01)
Free Cash Flow per Share
(0.56) (0.54) (0.59) (0.47)
Cash per Share
4.59 5.15 7.48 3.10
Shareholders Equity per Share
4.64 5.20 7.26 3.00
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
4.64 5.20 7.26 3.00
Free Cash Flow
(63.87) (61.64) (51.95) (41.63)
Working Capital
502.74 566.90 615.79 248.48
Capital Expenditures
(2.18) (3.00) (4.00) (1.12)
Net Current Asset Value
498.15 563.20 611.93 244.47
EV/EBIT
— — — —
Capex to Sales
0.00 0.00 0.00 0.00
Other line items
Average Payables
5.33 7.33 8.76 4.83
Average Assets
430.84 481.24 461.71 278.14
Average Common Equity
397.18 447.91 407.75 239.41

Fold the line items

Columns are period end dates